无转移生存是局限性前列腺癌总生存的强替代终点
该研究基于28项随机试验的28905例患者个体数据,评估局限性前列腺癌中无病生存(DFS)和无转移生存(MFS)对总生存(OS)的替代性。结果显示MFS与OS在患者水平和试验水平均强相关,治疗效应对MFS与OS的相关性R²为0.92(95%CI 0.81-0.95),优于DFS。
要点
- MFS与OS在患者水平Kendall τ为0.91,DFS为0.85。
- 试验水平治疗效应对MFS与OS的R²为0.92(95%CI 0.81-0.95)。
- MFS是局限性前列腺癌总生存的强替代终点。
核心结论
- MFS是局限性前列腺癌总生存的强替代终点,该人群存在显著的前列腺癌死亡风险。
研究设计与样本
- 截至2013年6月共识别102项已完成或正在进行的随机试验,从28项试验收集28905例患者个体数据。
- DFS分析纳入24项试验的21140例患者,MFS分析纳入19项试验的12712例患者。
- 采用两阶段荟萃分析验证模型评估DFS和MFS对OS的替代性。
主要发现
- 试验入组患者时间为1987年至2011年,中位随访10年后,21140例男性中45%发生DFS事件,12712例男性中45%发生MFS事件。
- DFS和MFS分析中分别有61%和90%的患者来自放疗试验,分别有63%和66%的患者为高危疾病。
- 患者水平Kendall τ与OS的相关性:DFS为0.85,MFS为0.91。
- 试验水平8年OS率对5年DFS和MFS率加权线性回归的R²分别为0.86(95%CI 0.78-0.90)和0.83(95%CI 0.71-0.88)。
- 治疗效应(以对数风险比衡量)与OS的相关性:DFS的R²为0.73(95%CI 0.53-0.82),MFS的R²为0.92(95%CI 0.81-0.95)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Adjuvant therapy for intermediate-risk and high-risk localized prostate cancer decreases the number of deaths from this disease. Surrogates for overall survival (OS) could expedite the evaluation of new adjuvant therapies. Methods By June 2013, 102 completed or ongoing randomized trials were identified and individual patient data were collected from 28 trials with 28,905 patients. Disease-free survival (DFS) and metastasis-free survival (MFS) were determined for 21,140 patients from 24 trials and 12,712 patients from 19 trials, respectively. We evaluated the surrogacy of DFS and MFS for OS by using a two-stage meta-analytic validation model by determining the correlation of an intermediate clinical end point with OS and the correlation of treatment effects on both the intermediate clinical end point and OS. Results Trials enrolled patients from 1987 to 2011. After a median follow-up of 10 years, 45% of 21,140 men and 45% of 12,712 men experienced a DFS and MFS event, respectively. For DFS and MFS, 61% and 90% of the patients, respectively, were from radiation trials, and 63% and 66%, respectively, had high-risk disease. At the patient level, Kendall's τ correlation with OS was 0.85 and 0.91 for DFS and MFS, respectively. At the trial level, R2 was 0.86 (95% CI, 0.78 to 0.90) and 0.83 (95% CI, 0.71 to 0.88) from weighted linear regression of 8-year OS rates versus 5-year DFS and MFS rates, respectively. Treatment effects-measured by log hazard ratios-for the surrogates and OS were well correlated ( R2, 0.73 [95% CI, 0.53 to 0.82] for DFS and 0.92 [95% CI, 0.81 to 0.95] for MFS). Conclusion MFS is a strong surrogate for OS for localized prostate cancer that is associated with a significant risk of death from prostate cancer.
引用
- Xie W, Regan MM, Buyse M, et al. Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer. J Clin Oncol. 2017. PMID: 28796587. doi:10.1200/JCO.2017.73.9987
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。